IAP-0971 is under clinical development by Sunho (China) Biopharmaceutical and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IAP-0971’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IAP-0971 overview
IAP-0971 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC), lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, non muscle invasive bladder cancer (NMIBC), non-Hodgkin lymphoma, hepatitis B virus (HBV) infections, unspecified indication, non-squamous non-small cell lung cancer. The drug candidate is administered through intravesical, subcutaneous and intravenous drip. It acts by targeting PD1 and IL15. It is being developed based on Armed ImmunoCytokine (AIC) platform.
Sunho (China) Biopharmaceutical overview
Sunho (China) Biopharmaceutical (Sunho (China) Biopharmaceutical) is a healthcare service provider. It specializes in developing drugs for the treatment of cancer. Sunho (China) Biopharmaceutical is headquartered in Chengdu, China.
For a complete picture of IAP-0971’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
